Cellda completes a new share issue of approximately SEK 3,7 million

In July Cellda AB (Cellda) completed a new share issue of approximately SEK 3,7 million. A number of existing shareholders and one new shareholder participated in the share issue. Cellda intends to use the new funding to further develop its software, Cellda® Prostate, for a more effective and consistent diagnosis of prostate cancer benefiting both patients and healthcare providers.

Ready to Transform Cancer Diagnosis?

Join Us in the Future of Healthcare

Discover how Cellda AB is revolutionizing prostate cancer diagnostics. Join the future today.